A protein complex of LCN2, LOXL2 and MMP9 facilitates tumour metastasis in oesophageal cancer
Authors:
Open Access
- 4 October 2023
- journal article
- research article
- Published by Wiley in Molecular Oncology
- Vol. 17 (11) , 2451-2471
Abstract
During malignant tumour development, the extracellular matrix (ECM) is usually abnormally regulated. Dysregulated expression of lysyl oxidase‐like 2 (LOXL2), matrix metalloproteinase 9 (MMP9) and lipocalin 2 (LCN2) are associated with ECM remodelling. In this study, protein–protein interaction assays indicated that LCN2 and LOXL2 interactions and LCN2 and MMP9 interactions occurred both intracellularly and extracellularly, but interactions between LOXL2 and MMP9 only occurred intracellularly. The LCN2/LOXL2/MMP9 ternary complex promoted migration and invasion of oesophageal squamous cell carcinoma (ESCC) cells, as well as tumour growth and malignant progression in vivo, while the iron chelator deferoxamine mesylate (DFOM) inhibited ESCC tumour growth. Co‐overexpression of LCN2, LOXL2 and MMP9 enhanced the ability of tumour cells to degrade fibronectin and Matrigel, increased the formation and extension of filopodia, and promoted the rearrangement of microfilaments through upregulation of profilin 1. In addition, the LCN2/LOXL2/MMP9 ternary complex promoted the expression of testican‐1 (SPOCK1), and abnormally activated the FAK/AKT/GSK3β signalling pathway. In summary, the LCN2/LOXL2/MMP9 ternary complex promoted the migration and invasion of cancer cells and malignant tumour progression through multiple mechanisms and could be a potential therapeutic target.Keywords
Funding Information
- National Natural Science Foundation of China (81672473)
This publication has 50 references indexed in Scilit:
- Iron Deprivation in Cancer––Potential Therapeutic ImplicationsNutrients, 2013
- Iron and cancer: more ore to be minedNature Reviews Cancer, 2013
- Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic BackgroundMolecular Cancer Therapeutics, 2012
- Lipocalin 2 in cancer: When good immunity goes badCancer Letters, 2012
- A Perspective on Cancer Cell MetastasisScience, 2011
- Neutrophil gelatinase-associated lipocalin and its receptor: independent prognostic factors of oesophageal squamous cell carcinomaJournal of Clinical Pathology, 2010
- Inhibition of Lipocalin 2 Impairs Breast Tumorigenesis and MetastasisCancer Research, 2009
- Genome-Wide Association Analyses Identify SPOCK as a Key Novel Gene Underlying Age at MenarchePLOS Genetics, 2009
- Matrigel: Basement membrane matrix with biological activitySeminars in Cancer Biology, 2005
- The High Molecular Weight Urinary Matrix Metalloproteinase (MMP) Activity Is a Complex of Gelatinase B/MMP-9 and Neutrophil Gelatinase-associated Lipocalin (NGAL)Journal of Biological Chemistry, 2001